RET (rearranged during transfection) fusions are most commonly found in thyroid cancer, whereas in PDAC they occur in <1% of all cases.236RET fusion leads to permanent, ligand-independent activation of the RET pathway.236 Selpercatinib is a selective RET kinase inhibitor and has also been used in a basket study in 12 patients with PDAC.236 PDAC patients showed a response rate of 55% representing a higher response rate compared to other tumor entities. The gene discussed is RET; the disease is thyroid cancer.